|
Utility inputs for disease states
|
|
Stable disease: ceritinib
|
0.81
|
ASCEND-4 (Soria et al. [5])
|
|
Treatment response: Ceritinib
|
0.81
|
|
Stable disease: crizotinib
|
0.81
|
Felip et al. [22, 26]
|
|
Treatment response: Crizotinib
|
0.81
|
|
Disease progression: all treatments
|
0.64
|
Chouaid et al. [27]
|
|
Hazard ratios
|
|
PFS: Ceritinib vs. Crizotinib
|
0.64 (0.47, 0.87)
|
Li et al. [17]
|
|
OS: Ceritinib vs. Crizotinib
|
0.82 (0.54, 1.27)
|
|
Unit cost
|
|
Ceritinib (450 mg)
|
$52.77 per pill
|
Hong Kong Hospital Authority [1]
|
|
Crizotinib (250 mg)
|
$113.21 per pill
|
|
Relative dose intensity
|
|
Ceritinib
|
92.2%
|
ASCEND-8 [6]
|
|
Crizotinib
|
92.0%
|
PROFILE 1014 (Australian Department of Health) [15]
|
|
Monthly medical costs/ pre-progression frequency/post-progression frequency
|
|
Cancer nurse
|
$12.82/ 0.1 time per month/0.1 time per month
|
Hong Kong Hospital Authoritya
|
|
Outpatient visit
|
$142.31/ 1 time per month / 1.08 times per month
|
|
Pharmacist
|
$49.36/ 1 time per month /0.1 time per month
|
|
Complete blood count
|
$17.31 / 1 time per month / 1.08 times per month
|
|
CT scan
|
$1,730.77/ 0.25 time per month / 0.18 time per month
|
|
MRI
|
$602.56/ 0.17 time per month /0.12 time per month
|
|
X-Ray
|
$24.36/ 1 time per month / 1.08 times per month
|
|
Serum chemistry
|
$116.03/ 1 time per month / 1.08 times per month
|
|
Total post-progression treatment costs
|
|
Ceritinib
|
$11,142.92
|
ASCEND-4; PROFILE 1014 [15]; Hong Kong Hospital Authority [1] and literature
|
|
Crizotinib
|
$10,385.68
|
|
Terminal care cost
|
$24,089.00
|
Wong et al. [25]
|
|
Costs associated with AEs
|
|
Ceritinib
|
$2,024.93
|
ASCEND-8 (Cho et al. [6] PROFILE 1014 (Solomon et al. [15]) Hong Kong Hospital Authority [1]
|
|
Crizotinib
|
$1,236.39
|
